Magnesium and Metabolic Syndrome

Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00603499

Enrollment

Registered

2008-01-29

Start date

2006-07-31

Completion date

2007-11-30

Last updated

2008-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, High Blood Pressure, Hypomagnesemia

Keywords

Diabetes, Hypertension, Hypomagnesemia

Brief summary

Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension. Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo. Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile

Interventions

DIETARY_SUPPLEMENTMagnesium chloride

Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.

OTHERPlacebo

Subjects in the control group received inert placebo once per day during 4 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Decreased serum magnesium levels * Uncomplicated hypertension * 40 and 75 years of age * Men and Women

Exclusion criteria

* Chronic diarrhea * Alcohol intake (equal or more than 30 g per day) * Use of diuretics and/or calcium antagonists drugs * Previous oral magnesium supplementation * Ischemic diseases; AND * Reduced renal function

Design outcomes

Primary

Measure	Time frame
Reduction in the systolic and diastolic blood pressures	2 y

Secondary

Measure	Time frame
Average increase of serum magnesium levels Changes in lipid profile	2 y

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026